DUBLIN--(BUSINESS WIRE)--Sep 7, 2018--The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends" report has been added to ResearchAndMarkets.com's offering.

CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment is the biggest breakthrough since the introduction of chemotherapy. Already two products (Kymriah and Yescarta) have been approved by the U.S. FDA and European EMA for different cancer indications.

CAR-T cell therapy has swept the biotech industry by storm in recent years, creating hope that it could welcome in a new age of cancer treatment. However, the remarkable success stories have come from targeting CD19, which is now considered an antigen that holds the key to a limited range of blood cancers. Presently, this hematological arena is a highly competitive therapy space that is being shared between among leading CAR-T companies.

Scientists, investors and developers invariably agree that the key to longer-term success in this space depends on solving two major problems: identifying antigens other than CD19 that can be targeted with CAR-T therapy with strong efficacy and going beyond liquid cancers into solid tumor indications. CAR-T cell products to deal with solid tumors will undoubtedly offer a larger market potential.

However, it is not an easy task to identify the antigens found on the cells of solid tumors. There are reasons why CD19 is the most common target. It is seen solely on B cells, whose destruction via CAR-T therapy offers a straightforward route for treating B-cell leukemias and lymphomas. At the same time, loss of the body's B cells is not particularly problematical, because their antibody-producing function can be reinstated by injecting intravenous immunoglobulin (IVIG) to patients.

Currently, the only two non-CD19-directed CAR-T therapies are those that target CD22 in B-cell malignancies and B-cell maturation antigen (BCMA) in multiple myeloma. CD22 is structurally analogous to CD19, while BCMA is an antigen expressed on plasma cells, whose functional loss can also be replaced with IVIG.

The problem with solid tumors is that there is little evidence of CAR-T being able to overcome the numerous difficulties that exist for these to be targeted efficiently. However, both academic and commercial groups are racing against time to identify the antigens on solid tumor cells and develop suitable CAR-T cells, because it represents large market potential.

There are several reasons which make solid tumors difficult to treat using CAR-T cell therapies. Globally, solid tumors outnumber the hematological tumors by 10 to one. In 2015, Novartis and PENN reported that their CART-meso failed to show any effect in patients with mesothelioma, ovarian cancer and pancreatic cancer. Moreover, there was very poor persistence of CAR-T cells in the patients.

The difficulty with solid tumors is that they are usually surrounded by a hostile, immuno-suppressive microenvironment. This environment presents many inhibitory factors that prevent CAR-T cells from reaching them. A typical CAR-T approach will not have success under these conditions. For this reason, Juno and Novartis are engaging in constructing CAR-T cells with novel designs that incorporate additional elements to boost activity within this setting. Currently, these products are in preclinical development.

Driving Forces for the CAR-T Therapy Market

Increasing investment flowing into CAR-T cell research Landmark approvals of CAR-T cell therapies by the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA) Major acquisitions within the CAR-T industry Large IPOs within the CAR-T industry

Key Topics Covered:

1. Report Overview

2. History of CAR-T Cell Therapy

3. CAR-T Manufacturing Processes

4. Structure of a CAR-T Cell

5. Number of CAR-T Companies, their Recent Activities

6. Tumor-Associated Target Antigens

7. Target Diseases for CAR-T Cell Therapy

8. Pricing and Payment Models for CAR-T Therapies

9. Medical Facilities Offering CAR-T Therapies

10. CAR-T Therapy Patent Landscape

11. Deals, Fundings, Partnerships and Collaborations

12. The Landscape of CAR-T Cell Therapy Clinical Trials

13. CAR-T Cell Products in the Market

14. Insurance Coverage for CAR-T Therapy

15. Commercial Threats For CAR-T Industry

16. Challenges to Overcome

17. Market Analysis

18. Company Profiles

AbbVie Inc. Adaptimmune Therapeutics PLC Amgen, Inc. Atara Biotherapeutics, Inc. Aurora Biopharma, Inc. Autolus Therapeutics PLC Bellicum Pharmaceuticals, Inc. BioAtla LLC bluebird bio Carina Biotech CARsgen Therapeutics, Ltd. CARTherics Cellectis Celularity Celyad SA Creative Biolabs DiaCarta, Inc. Endocyte, Inc. F1 Oncology, Inc. Fate Therapeutics Inc. Humanigen, Inc. Immune Therapeutics, Inc. Intrexon, Corp. Juno Therapeutics, Inc. Kite Pharma, Inc. Lion TCR Pte Ltd. MaxCyte, Inc. Mesoblast, Ltd. Minerva Biotechnologies Corp. Mustang Bio, Inc. Novartis AG Oxford BioMedica PLC. PeproMene Bio Inc. Pfizer, Inc. Posedia Therapeutics Inc. Precision Biosciences, Inc. ProMab Biotechnologies Inc. Servier Oncology Sorrento Therapeutics, Inc. TC Biopharm Ltd. Tessa Therapeutics Pte Ltd. TILT Biotherapeutics Ltd. Tmunity Therapeutics Inc. TrakCel Ltd. Xyphos ZIOPHARM Oncology, Inc. For more information about this report visit https://www.researchandmarkets.com/research/2f4kdn/global_cart_cell?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180907005113/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics,Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/07/2018 05:04 AM/DISC: 09/07/2018 05:04 AM